

## Appendix 1: Documents purposively selected for discourse analysis

### Policy documents by government ministers and departments

(Atkins, 2018; Brine & Newton, 2017; Churchill, 2019; DHSC, 2018; HM Government, 2021; Home Office, 2022; Javid, 2018a, 2018b; Javid & Hancock, 2018; Malthouse, 2020b, 2020a, 2021; MHCLG, 2019; MoJ, 2019; Patel, 2020, 2021; PHE, 2016, 2019; Scottish Drug Deaths Taskforce, 2020; Scottish Government, n.d., 2020, 2020; UK Government, 2021)

### Policy documents from political parties

(Conservative Party, 2019; Green Party of England, 2019; Labour Party, 2019; Liberal Democrats, undated)

### Policy reports by quangos, advisers and advisory committees

(ACMD, 2015a, 2016e, 2016a, 2016d, 2016a, 2016b, 2018c, 2018b, 2018d, 2018a, 2018c, 2019c, 2019a, 2019e, 2019g, 2019d, 2019b, 2020d, 2020c, 2020c, 2020a, 2020b, 2021; ACMD Recovery Committee, 2017; CRED, 2021; Lammy, 2017)

### Reports and statements by parliamentary committees

(APPGDPR, 2016; Health and Social Care Committee, 2019; Scottish Affairs Committee, 2019; Webster, 2017)

### Speeches by ministers

(Javid, 2021)

### Parliamentary debates

#### House of Commons:

- Misuse of Drugs Act 1971 (14<sup>th</sup> December 2021)
- Medical cannabis (access) bill (10<sup>th</sup> December 2021)
- Ten-year drug strategy (6<sup>th</sup> December 2022)
- Medical cannabis: alleviation of health conditions (4<sup>th</sup> November 2021)
- Dame Carol Black's independent review of drugs report (27<sup>th</sup> October 2021)
- Misuse of Drugs Act and health outcomes (8<sup>th</sup> September 2021)
- Medicinal cannabis (6<sup>th</sup> September 2021)
- Misuse of Drugs Act (17<sup>th</sup> June 2021)
- Problem drug use (29<sup>th</sup> September 2020)
- County lines drug gangs (28<sup>th</sup> October 2019)
- Drug consumption rooms (Glasgow) (24<sup>th</sup> July 2019)
- Drug treatment services (16<sup>th</sup> July 2019)
- Dangerous drugs (3<sup>rd</sup> July 2019)
- Medical cannabis under prescription (20<sup>th</sup> May 2019)
- Drug policy (23<sup>rd</sup> October 2018)
- Drug-related harm (24<sup>th</sup> July 2018)
- Cannabis-based medicines (19<sup>th</sup> June 2018)
- Medical cannabis (20<sup>th</sup> February 2018)
- Drug consumption rooms (17<sup>th</sup> January 2018)
- Drug Addiction (20<sup>th</sup> November 2017)
- Drug policy (18<sup>th</sup> July 2017)
- Cannabis (12<sup>th</sup> October 2015)

#### House of Lord

- Drugs: Black review (19<sup>th</sup> October 2021)
- Drugs: methadone (28<sup>th</sup> October 2019)
- Cannabis: medical use (16<sup>th</sup> July 2018)
- Cannabis (12<sup>th</sup> March 2018)
- Cannabis (7<sup>th</sup> September 2017)
- Drug policy: departmental responsibilities (7<sup>th</sup> February 2017)

- Drug Policy (21<sup>st</sup> November 2016)
- Drugs (4<sup>th</sup> February 2016)
- Drugs: cannabis (17<sup>th</sup> June 2015)

#### Scottish Parliament

- Joint committee meeting: Reducing drug deaths in Scotland and tackling problem drug use (2<sup>nd</sup> February 2022)
- Criminal Justice Committee: Misuse of Drugs and the Criminal Justice System (27<sup>th</sup> October 2021)
- Health, Social Care and Sport Committee: session 6 priorities (drug policy) (14<sup>th</sup> September 2021)
- Drug policy (20<sup>th</sup> January 2021)
- Health and Social Care Committee: drug policy (9<sup>th</sup> March 2021)
- Drug-related deaths (7<sup>th</sup> January 2020)
- Supervised drug consumption facilities (5<sup>th</sup> November 2019)
- Drug strategy (22<sup>nd</sup> May 2018)
- Safer Injecting Facilities (19<sup>th</sup> April 2018)

#### Media articles, press releases and blog posts

(ACMD, 2015b, 2016c, 2019f; Drug Science, 2019b; English & Doughty, 2017; Jones et al., 2018; LCDPR, 2018; Pryor, 2018, 2020, p. 202; Rudd, 2017; Worstall, n.d.)

#### Documents from non-governmental organisations

(Bartle, 2019; Bhatarah et al., 2021; Carre & Ali, 2019; Centre for Social Justice, 2018; CSJ, 2018; Drug Science, 2016, 2019a; Fisher & Measham, 2018; Garius & Ali, 2022; Keeling, 2021a, 2021b; King et al., 2021; King & Moore, 2020; MCCS & Drug Science, 2021; McCulloch, 2017a, 2017b; McCulloch et al., 2018; McCulloch & Furlong, n.d.; Moore, 2019; Moore et al., 2021; North, 2017a, 2017b; Nutt, 2022; Power, 2017; Pryor, 2018, 2020; Pryor & McCulloch, 2019; Release, 2018, 2019; Rolles et al., 2016; Rucker et al., 2020; SDF, 2018, 2021; SDF & Scottish Government, 2019; Shiner et al., 2018; Starling, 2016; Stevens, 2017; Transform, 2015, 2017a, 2017b, 2018c, 2018a, 2018b, 2020, 2022)

#### Inclusion criteria:

- Published since May 2015 (general election).
- Is directly relevant to the drug policy discussions covered in this book in the UK, especially England and Scotland (i.e. policy on medical cannabis, drug-related deaths, and the UK's ten year drug strategy from 2021).
- Included types of document are: policy reports by government departments, quasi non-government organisations (quangos), independent advisers and advisory panels (e.g. Advisory Council on the Misuse of Drugs), speeches in and outside UK and Scottish Parliaments by government ministers, debates in these Parliaments on drug policy, relevant media articles by policy actors.

#### Exclusion criteria

- Relates directly to the Psychoactive Substances Act 2016 or to drug decriminalisation.

Add:

Ministerial speeches

- ACMD. (2015a). *How can opioid substitution therapy be optimised to maximise recovery outcomes for service users?* Home Office.
- ACMD. (2015b). *Press release: Quality of treatment for heroin users under threat.* Home Office.
- ACMD. (2016a). *ACMD Response to Drug Strategy.* Home Office.
- ACMD. (2016b). *Phytocannabinoids: A review of the generic definition.* Home Office.
- ACMD. (2016c). *Press release: ACMD tells ministers drug-related deaths will continue to rise if treatment programmes are not maintained.* Home Office.  
<https://www.gov.uk/government/news/acmd-tells-ministers-drug-related-deaths-will-continue-to-rise-if-treatment-programmes-are-not-maintained>
- ACMD. (2016d). *Reducing opioid-related deaths in the UK.* Home Office.
- ACMD. (2016e). *The extent to which commissioning structures, the financial environment and wider changes to health and social welfare impact on recovery outcomes for individuals and communities.* Advisory Council on the Misuse of Drugs.
- ACMD. (2018a). *Further advice on scheduling of cannabis-derived medicinal products.* Home Office.
- ACMD. (2018b). *Response to consultation on cannabis-based medicinal products.* Home Office.
- ACMD. (2018c). *Scheduling of Cannabis-derived medicinal products 19.* Home Office.
- ACMD. (2018d). *Vulnerabilities and substance use.* Home Office.
- ACMD. (2019a). *ACMD framework for the assessment of the various impacts of rescheduling Cannabis-based Products for Medicinal use in humans (CBPMs) to Schedule 2 under the Misuse of Drugs Regulations 2001.* Home Office.
- ACMD. (2019b). *Advice on 2,4-Dinitrophenol.* Home Office.
- ACMD. (2019c). *Custody-Community Transitions.* Home Office.
- ACMD. (2019d). *Future use and purpose of Temporary Class Drug Orders (TCDOs).* Home Office.
- ACMD. (2019e). *Misuse of fentanyl and fentanyl analogues.* Home Office.
- ACMD. (2019f). *Press release: Avoid Friday prison release to prevent drug relapse and deaths.* Home Office.
- ACMD. (2019g). *Self-commissioned workstreams for 2020.* Home Office.
- ACMD. (2020a). *Advice on Epidyolex.* Home Office.
- ACMD. (2020b). *Assessment of the harms of gamma-hydroxybutyric acid, gamma-butyrolactone, and closely related compounds.* Home Office.
- ACMD. (2020c). *Standard Operating Procedure for using evidence in ACMD reports.* Home Office.
- ACMD. (2020d). *Synthetic cannabinoid receptor agonists.* Home Office.
- ACMD. (2021). *ACMD advice on consumer cannabidiol (CBD) products.*
- ACMD Recovery Committee. (2017). *Commissioning impact on drug treatment: The extent to which commissioning structures, the financial environment and wider changes to health and social welfare impact on drug misuse treatment and recovery.* Home Office.
- APPGDPR. (2016). *Access to medicinal cannabis: Meeting patient needs.* All-Party Parliamentary Group on Drug Policy Reform.
- Atkins, V. (2018). *Reducing Opioid-Related Deaths in the UK: further response on drug consumption rooms.* Home Office.
- Bartle, J. (2019). *Room for Improvement: How drug consumption rooms save lives.* Adam Smith Institute.
- Bhatarah, P., Duffy, P., Yates, A., & O'Sullivan, S. (2021). *Response to the ACMD on CBD from ACI and CMC.* Association for the Cannabis Industry and Centre for Medical Cannabis.
- Brine, S., & Newton, S. (2017). *Government Response to Four Reports from the Advisory Council on the Misuse of Drugs.* Home Office.
- Carre, Z., & Ali, A. (2019). *Finding a Needle in a Haystack: Take-Home Naloxone in England 2017/18.* Release.
- Centre for Social Justice. (2018). *Desperate for a Fix: Using shop theft and a Second Chance Programme to get touch on prolific drug-addicted offenders.* Centre for Social Justice.

- Churchill, J. (2019). *ACMD ageing cohort of drug users report: Government response*. Department of Health and Social Care.
- Conservative Party. (2019). *Get Brexit Done. Unleash Britain's Potential*. Conservative Party.
- CRED. (2021). *Commission on Race and Ethnic Disparities: The Report* (Issue March). Cabinet Office.
- CSJ. (2018). *Cannabis: The case against legalisation*. Centre for Social Justice.  
<https://doi.org/10.1136/bmj.314.7085.970>
- DHSC. (2018). *Commissioning impact on drug treatment: Government response*. Department of Health and Social Care.
- Drug Science. (2016). *Cannabis and Cannabis Resin: Pre-Review Report*. Drug Science.
- Drug Science. (2019a). *Drug Science launches Working Group on Medical Cannabis*. Drug Science.
- Drug Science. (2019b). *Press Release: Government decision on cannabis-related medicinal products draws criticism from independent scientific body*, Drug Science. Drug Science.
- English, R., & Doughty, S. (2017, September 21). *Prince William branded 'naive' over legalising drugs remark*. Mail Online. <http://www.dailymail.co.uk/~article-4904944/index.html>
- Fisher, H., & Measham, F. (2018). *Night Lives: Reducing Drug-Related Harm in the Night Time Economy*. Volteface.
- Garius, L., & Ali, A. (2022). *Regulating Right, Repairing Wrongs: Exploring Equity and Social Justice Initiatives within UK Cannabis Reform*. <https://www.release.org.uk/publications/cannabis-regulating-right>
- Green Party of England. (2019). *If not now, when? Green Party General Election Manifesto*.
- Health and Social Care Committee. (2019). *Drug policy: First report of session 2019*. House of Commons.
- HM Government. (2021). *From harm to hope: A 10-year drugs plan to cut crime and save lives*. HM Government.
- Home Office. (2022). *Government response to the ACMD on CBPMs in humans*. Home Office.
- Javid, S. (2018a). *Commission to the ACMD: scheduling under the Misuse of Drugs Regulations 2001*. Home Office.
- Javid, S. (2018b). *Government response to the ACMD: Cannabis derived medicinal products*. Home Office.
- Javid, S. (2021). Dame Carol Black's Independent Review of Drugs: Publication of Part 2. *Hansard*, 698(8th July 2021).
- Javid, S., & Hancock, M. (2018). *Response to ACMD: cannabis-derived medicinal products, 21 September 2018*. Home Office and Department of Health and Social Care.
- Jones, A., Jamieson, D., & Hogg, R. (2018). *Statement on 'Reducing Opioid-Related Deaths in the UK: further response on drug consumption rooms'*. Offices of the Police and Crime Commissioners for North Wales, West Midlands and Durham.
- Keeling, P. (2021a). *A joint response to the new drug strategy*. Collective Voice.
- Keeling, P. (2021b). *If not now, when?* Collective Voice.
- King, D., Bhatarah, P., Duffy, P., Yates, A., & O'Sullivan, S. (2021). *A Step-by-Step Approach: Establishing the Zero Threshold in CBD Products*. Conservative Drug Policy Reform Group and Association for the Cannabis Industry.
- King, D., & Moore, A. (2020). *The UK Review of the Medical Cannabis: The needs of a nation*. Conservative Drug Policy Reform Group.
- Labour Party. (2019). *It's time for a real change. The Labour Party Manifesto 2018*.
- Lammy, D. (2017). *The Lammy Review: An independent review into the treatment of, and outcomes for, Black, Asian and Minority Ethnic individuals in the Criminal Justice System*. Cabinet Office.
- LCDPR. (2018). *Labour members launch new campaign calling for changes in UK drug policy*. Labour Campaign for Drug Policy Reform. <https://www.labourdrugpolicy.com/new-blog/2018/7/17/labour-members-launch-new-campaign-calling-for-change-in-uk-drug-policy>

- Liberal Democrats. (undated). *Let's Legalise Cannabis*. Liberal Democrats.  
<https://www.libdems.org.uk/cannabis>
- Malthouse, K. (2020a). *Response to the ACMD recommendation: Epidyolex*. Home Office.
- Malthouse, K. (2020b). *Response to the ACMD report on the misuse of fentanyl and fentanyl analogues*. Home Office.
- Malthouse, K. (2021). *Letter to ACMD chair on drug misuse prevention review*. Home Office.
- MCCS, & Drug Science. (2021). *Commentary and critique on the BNPA publication: Guidance on the use of cannabis-based products for medicinal use in children and young people with epilepsy*. Medical Cannabis Clinical Society and Drug Science.
- McCulloch, L. (2017a). *Back Yard: An investigation into the feasibility of establishing drug consumption rooms*. Volteface.
- McCulloch, L. (2017b). *Black Sheep: An Investigation into Existing Support for Problematic Cannabis Use*. Volteface.
- McCulloch, L., & Furlong, S. (n.d.). *Making the Grade: School prevention, identification and responses to drug-related harm*. Volteface and Mentor UK. Retrieved 31 March 2022, from <https://volteface.me/app/uploads/2019/04/Volteface-Making-the-Grade-Full-Report.pdf>
- McCulloch, L., Matharu, H., & North, P. (2018). *The Children's Inquiry*. Volteface.
- MHCLG. (2019). *Drug related harms in homeless populations: Government response*. Ministry of Housing, Communities and Local Government.
- MoJ. (2019). *ACMD Custody-Community Transitions report: Government Response*. Ministry of Justice.
- Moore, A. (2019). *Public attitudes to drugs in the UK: Is the UK ready for drug policy reform?* Conservative Drug Policy Reform Group.
- Moore, A., Webster, T., Atkins, D., & Stone, R. (2021). *Making UK drug policy a success: Reforming the policymaking process*. Conservative Drug Policy Reform Group.
- North, P. (2017a). *Icelandic Youth*. Volteface.
- North, P. (2017b). *Street Lottery: Cannabis potency and mental health*. Volteface.
- Nutt, D. (2022). *Why doctors have a moral imperative to prescribe and support medical cannabis*. Drug Science.
- Patel, P. (2020). *Home Secretary's commissioning letter to the chair of the ACMD*. Home Office.
- Patel, P. (2021). *Response to the ACMD on GHB, GBL and closely related compounds*. Home Office.
- PHE. (2016). *Understanding and preventing drug-related deaths The report of a national expert working group to investigate drug-related deaths in England*. Public Health England.
- PHE. (2019). *Principles for engaging with industry stakeholders*. Public Health England.  
<https://www.gov.uk/government/publications/principles-for-engaging-with-industry-stakeholders/principles-for-engaging-with-industry-stakeholders#commodity-specific-guidance>
- Power, M. (2017). *Green Screen*. Volteface.
- Pryor, D. (2018). Norway is aiming to decriminalise drugs. The UK should choose legalisation. *The Guardian*. <https://www.theguardian.com/commentisfree/2018/jan/18/norway-decriminalised-drugs-uk-chose-legalisation-policy>
- Pryor, D. (2020). *Britain's Drug Death Disgrace*. Adam Smith Institute.  
<https://www.adamsmith.org/blog/britains-drug-death-disgrace>
- Pryor, D., & McCulloch, L. (2019). *The Green Light: How legalising and regulating cannabis will reduce crime, protect children and improve safety*. Adam Smith Institute.
- Release. (2018). *Twitter thread on Victoria Atkins letter on drug consumption rooms*.  
[https://twitter.com/Release\\_drugs/status/984829019836297216](https://twitter.com/Release_drugs/status/984829019836297216)
- Release. (2019). *Saving Lives: Best practice guidance on the provision of naloxone for people who might experience or witness an opioid overdose*. Release.

- Rolles, S., Barton, M., Eastwood, N., Lloyd, T., Measham, F., Nutt, D., & Sumnall, H. (2016). *A framework for a regulated market for cannabis in the UK: Recommendations from an expert panel*. Liberal Democrats.
- Rucker, J., Schnall, J., D’Hotman, D., King, D., Davis, T., & Joanne, N. (2020). *Medicinal Use of Psilocybin: Reducing restrictions on research and treatment*. Adam Smith Institute and Conservative Drug Policy Reform Group.
- Rudd, A. (2017). *Our Drugs Strategy Will Tackle a Corrosive, Creeping Threat Destroying Countless Lives*. Huffington Post. [http://www.huffingtonpost.co.uk/amber-rudd/drug-strategy\\_b\\_17474964.html](http://www.huffingtonpost.co.uk/amber-rudd/drug-strategy_b_17474964.html)
- Scottish Affairs Committee. (2019). *Problem drug use in Scotland*. <https://publications.parliament.uk/pa/cm201919/cmselect/cmselect/cmselect/cmselect/44/4402.htm>
- Scottish Drug Deaths Taskforce. (2020). *Medication Assisted Treatment (MAT) Standards for Scotland: Access, Choice, Support. Consultation on the standards* (Issue May). Scottish Drug Deaths Taskforce.
- Scottish Government. (n.d.). *International Approaches to Drug Law Reform*. Scottish Government. <https://www.gov.scot/publications/international-approaches-drug-law-reform/documents/>
- Scottish Government. (2020). *Evidence-Based Strategies for Preventing Drug-Related Deaths in Scotland: Our emergency response* (Issue January). The Scottish Government.
- SDF. (2018). *The Control of Drugs—Issues in Harm Reduction Series*. Scottish Drugs Forum.
- SDF. (2021). *Drug-related deaths in Scotland: MSP Briefing*. Scottish Drugs Forum.
- SDF, & Scottish Government. (2019). *Staying Alive in Scotland—2019 Edition*. Scottish Drugs Forum.
- Shiner, M., Carre, Z., Delsol, R., & Eastwood, N. (2018). *The Colour of Injustice: ‘Race’, drugs and law enforcement in England and Wales*. Release.
- Starling, B. (2016). *The Tide Effect: How the world is changing its mind on cannabis legalisation*. Volteface and the Adam Smith Institute.
- Stevens, A. (2017). *Are Drug Consumption Rooms Viable in The UK?* Volteface.
- Transform. (2015). *The War on Drugs: Harming, not protecting, young people*. Transform Drug Policy Foundation.
- Transform. (2017a). *Heroin Assisted Treatment (HAT): Saving lives, improving health, reducing crime*. Transform Drug Policy Foundation.
- Transform. (2017b). *Scottish Drug Policy Reform: Keeping vulnerable people safer by putting health first*. Transform Drug Policy Foundation.
- Transform. (2018a). *Drug Consumption Rooms: Saving lives, making communities safer*. Transform Drug Policy Foundation.
- Transform. (2018b). *Drug Safety Testing: Saving lives, increasing awareness*. Transform Drug Policy Foundation.
- Transform. (2018c). *Press Release: UK Drugs Minister Mised Parliament Say Canadian Lawyers and Scientists*. <http://www.tdpf.org.uk/blog/press-release-uk-drugs-minister-mised-parliament-say-canadian-lawyers-scientists>
- Transform. (2020). *Reforming Drugs Policies to Reduce the Trafficking and Exploitation of Vulnerable People*. Transform Drug Policy Foundation.
- Transform. (2022). *The Misuse of Drugs Act 1971: Counting the costs*. Transform Drug Policy Foundation.
- UK Government. (2021). *Drugs policy: Government Response to the Committees First Report of Session 2019*. House of Commons. <https://publications.parliament.uk/pa/cm5801/cmselect/cmselect/cmselect/cmselect/1178/117802.htm>
- Webster, R. (2017). *Drugs, Alcohol & Justice: A charter for change*. <https://www.russellwebster.com/charter-for-change/>
- Worstell, T. (n.d.). *Finally, a sensible drug policy*. Adam Smith Institute. Retrieved 31 March 2022, from <https://www.adamsmith.org/blog/finally-a-sensible-drug-policy>